JP2006176498A5 - - Google Patents

Download PDF

Info

Publication number
JP2006176498A5
JP2006176498A5 JP2005335154A JP2005335154A JP2006176498A5 JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5 JP 2005335154 A JP2005335154 A JP 2005335154A JP 2005335154 A JP2005335154 A JP 2005335154A JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hmg
coa reductase
reductase inhibitor
ubidecarenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005335154A
Other languages
Japanese (ja)
Other versions
JP4896501B2 (en
JP2006176498A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2005335154A priority Critical patent/JP4896501B2/en
Priority claimed from JP2005335154A external-priority patent/JP4896501B2/en
Publication of JP2006176498A publication Critical patent/JP2006176498A/en
Publication of JP2006176498A5 publication Critical patent/JP2006176498A5/ja
Application granted granted Critical
Publication of JP4896501B2 publication Critical patent/JP4896501B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (14)

ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを含有する、血中遊離脂肪酸を低下させるための医薬組成物。 A pharmaceutical composition for reducing blood free fatty acids, comprising an HMG-CoA reductase inhibitor and ubidecarenone. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを含有する、血中遊離脂肪酸及び血中トリグリセライドを同時に低下させるための医薬組成物。 A pharmaceutical composition for simultaneously reducing blood free fatty acid and blood triglyceride, comprising an HMG-CoA reductase inhibitor and ubidecarenone. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを含有する、高遊離脂肪酸血症を治療又は予防するための医薬組成物。 A pharmaceutical composition for treating or preventing hyperfree fatty acidemia, comprising an HMG-CoA reductase inhibitor and ubidecarenone. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを含有する、高遊離脂肪酸血症及び高トリグリセライド血症を同時に治療又は予防するための医薬組成物。 A pharmaceutical composition for simultaneously treating or preventing hyperfree fatty acidemia and hypertriglyceridemia, comprising an HMG-CoA reductase inhibitor and ubidecarenone. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを含有する、高遊離脂肪酸血症に起因する疾病を治療又は予防するための医薬組成物。 A pharmaceutical composition for treating or preventing a disease caused by hyperfree fatty acidemia, comprising an HMG-CoA reductase inhibitor and ubidecarenone. 高遊離脂肪酸血症に起因する疾病がインスリン抵抗性症候群である請求項５に記載の医薬組成物。 6. The pharmaceutical composition according to claim 5, wherein the disease caused by hyperfree fatty acidemia is insulin resistance syndrome. 高遊離脂肪酸血症に起因する疾病が高血圧症、動脈硬化関連疾患又は糖尿病である請求項５に記載の医薬組成物。 The pharmaceutical composition according to claim 5, wherein the disease caused by hyperfree fatty acidemia is hypertension, arteriosclerosis-related disease or diabetes. ＨＭＧ−ＣｏＡリダクターゼ阻害剤が、プラバスタチン、ロバスタチン、シンバスタチン、フルバスタチン、アトルバスタチン、ピタバスタチン、ロスバスタチン及びその薬理上許容される塩からなる群より選ばれる１種又は２種以上である、請求項１乃至請求項７から選択されるいずれか１項に記載の医薬組成物。 The HMG-CoA reductase inhibitor is one or more selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin and pharmacologically acceptable salts thereof. Item 8. The pharmaceutical composition according to any one of items 7 selected from item 7. ＨＭＧ−ＣｏＡリダクターゼ阻害剤が、プラバスタチンナトリウムである、請求項１乃至請求項７から選択されるいずれか１項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 7, wherein the HMG-CoA reductase inhibitor is pravastatin sodium. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとが同一の医薬組成物中に含有する配合剤である請求項１乃至請求項９のいずれか１項に記載の医薬組成物。   The pharmaceutical composition according to any one of claims 1 to 9, wherein the HMG-CoA reductase inhibitor and ubidecarenone are a combination drug contained in the same pharmaceutical composition. ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物とユビデカレノンを含有する医薬組成物とからなるキットである請求項１乃至請求項９のいずれか１項に記載の医薬組成物。   The pharmaceutical composition according to any one of claims 1 to 9, which is a kit comprising a pharmaceutical composition containing an HMG-CoA reductase inhibitor and a pharmaceutical composition containing ubidecarenone. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを同一の医薬組成物中に含有する請求項１乃至請求項９のいずれか１項に記載の医薬組成物の製造方法。   The method for producing a pharmaceutical composition according to any one of claims 1 to 9, wherein the HMG-CoA reductase inhibitor and ubidecarenone are contained in the same pharmaceutical composition. 高遊離脂肪酸血症治療剤を製造するための、請求項１乃至請求項１１のいずれか１項に記載の医薬組成物の使用。   Use of the pharmaceutical composition according to any one of claims 1 to 11 for producing a therapeutic agent for hyperfree fatty acidemia. ＨＭＧ−ＣｏＡリダクターゼ阻害剤とユビデカレノンとを同時に、順次又は別個に投与する高遊離脂肪酸血症の治療又は予防剤。   A therapeutic or prophylactic agent for hyperfree fatty acidemia, wherein an HMG-CoA reductase inhibitor and ubidecarenone are administered simultaneously, sequentially or separately.
JP2005335154A 2004-11-26 2005-11-21 Pharmaceutical composition having blood free fatty acid lowering action Expired - Fee Related JP4896501B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005335154A JP4896501B2 (en) 2004-11-26 2005-11-21 Pharmaceutical composition having blood free fatty acid lowering action

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004341493 2004-11-26
JP2004341493 2004-11-26
JP2005335154A JP4896501B2 (en) 2004-11-26 2005-11-21 Pharmaceutical composition having blood free fatty acid lowering action

Publications (3)

Publication Number Publication Date
JP2006176498A JP2006176498A (en) 2006-07-06
JP2006176498A5 true JP2006176498A5 (en) 2009-01-29
JP4896501B2 JP4896501B2 (en) 2012-03-14

Family

ID=36730936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005335154A Expired - Fee Related JP4896501B2 (en) 2004-11-26 2005-11-21 Pharmaceutical composition having blood free fatty acid lowering action

Country Status (1)

Country Link
JP (1) JP4896501B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012096998A (en) * 2009-02-27 2012-05-24 Kowa Co Stable capsule preparation and method for producing the same
TWI636783B (en) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 Stable formulations of pitavastatin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383432B1 (en) * 1989-01-18 1993-03-24 Merck & Co. Inc. Coenzyme q10 with hmg-coa reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
JP2003081873A (en) * 2001-06-28 2003-03-19 Takeda Chem Ind Ltd Prophylactic or therapeutic agent for organ functional disorder and organ insufficiency
EP1496881A4 (en) * 2002-04-23 2007-04-04 Nutrition 21 Inc Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance

Similar Documents

Publication Publication Date Title
RU2022100434A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING EPA AND CARDIOVASCULAR DRUG AND METHODS OF THEIR APPLICATION
JP2010047616A5 (en)
WO2008045170A3 (en) Statin and omega-3 fatty acids for reduction of apo-b levels
JP2015503588A5 (en)
JP2007523049A5 (en)
JP2008509132A5 (en)
JP2004537553A5 (en)
EA200970359A1 (en) STATIN AND OMEGA-3 FATTY ACIDS TO REDUCE ARO-B LEVELS
AR076835A1 (en) COMPOSITIONS OF ORAL DISINTEGRATION TABLETS THAT INCLUDE COMBINATIONS OF DRUGS IN ELEVATED AND REDUCED DOSE. METHOD.
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
NZ603207A (en) Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
JP2008515980A5 (en)
US20190224141A1 (en) Pharmaceutical Compositions Comprising a Statin and a Cannabinoid and Uses Thereof
WO2009059717A3 (en) Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
JP2005511619A5 (en)
JP2006176498A5 (en)
JP2014521738A5 (en)
JP2008063322A5 (en)
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
WO2013073884A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
RU2007148908A (en) COMPOSITIONS FOR REDUCING THE RISK OF ARCTHYME CAUSED BY MEDICINES
RU2014145102A (en) COMBINATION
JP2005522490A5 (en)
JPWO2006011495A1 (en) Treatment for hypercholesterolemia and / or hypertriglyceridemia
NZ603397A (en) Association of xanthine oxidase inhibitors and statins and use thereof